FIBROGEN INC - COMMON

FibroGen To Host Part I of Virtual KOL Investor Event Series to Review Pamrevlumab Clinical Program in Pancreatic Cancer on February 13, 2024

05 2 2024 04:00:00 提供 Nasdaq GlobeNewswire

FibroGen Announces Completion of the Pamrevlumab Arm in Precision Promise, Pancreatic Cancer Action Network’s Phase 2/3 Adaptive Platform Trial for Metastatic Pancreatic Cancer

25 1 2024 04:00:00 提供 Nasdaq GlobeNewswire

FibroGen Presents Data from Phase 3 MATTERHORN Trial of Roxadustat in Patients with Anemia of Lower Risk Transfusion-Dependent Myelodysplastic Syndromes at American Society of Hematology Annual Meeting

09 12 2023 14:02:00 提供 Nasdaq GlobeNewswire

FibroGen Reports Third Quarter 2023 Financial Results

06 11 2023 13:01:00 提供 Nasdaq GlobeNewswire

FibroGen to Report Third Quarter 2023 Financial Results

23 10 2023 04:00:00 提供 Nasdaq GlobeNewswire

FibroGen Announces Topline Results from LELANTOS-2, a Phase 3 Clinical Study of Pamrevlumab in Ambulatory Duchenne Muscular Dystrophy

29 8 2023 13:15:00 提供 Nasdaq GlobeNewswire

FibroGen Reports Second Quarter 2023 Financial Results

07 8 2023 13:01:00 提供 Nasdaq GlobeNewswire

FibroGen Announces Topline Results from Phase 3 ZEPHYRUS-1 Study of Pamrevlumab for the Treatment of Idiopathic Pulmonary Fibrosis

26 6 2023 04:04:00 提供 Nasdaq GlobeNewswire

FibroGen Announces Topline Results from LELANTOS-1 Phase 3 Clinical Study of Pamrevlumab in Non-Ambulatory Patients with Duchenne Muscular Dystrophy

07 6 2023 03:55:00 提供 Nasdaq GlobeNewswire

FibroGen to Present at Jefferies Global Healthcare Conference

06 6 2023 13:01:00 提供 Nasdaq GlobeNewswire

FibroGen Announces Positive Topline Results from China Pivotal Phase 3 Clinical Trial of Roxadustat for the Treatment of Chemotherapy Induced Anemia

18 5 2023 04:30:00 提供 Nasdaq GlobeNewswire

FibroGen Reports First Quarter 2023 Financial Results

08 5 2023 13:01:00 提供 Nasdaq GlobeNewswire

FibroGen Enters into Exclusive License for FOR46 with Fortis Therapeutics

08 5 2023 13:00:00 提供 Nasdaq GlobeNewswire

FibroGen Announces Results for MATTERHORN, a Phase 3 Clinical Study of Roxadustat for the Treatment of Anemia in Patients with Myelodysplastic Syndromes (MDS)

05 5 2023 04:30:00 提供 Nasdaq GlobeNewswire

FibroGen Announces Non-Dilutive Term Loan Financing for up to $150 Million with Morgan Stanley Tactical Value

01 5 2023 04:00:00 提供 Nasdaq GlobeNewswire

FibroGen to Report First Quarter 2023 Financial Results

24 4 2023 04:00:00 提供 Nasdaq GlobeNewswire

FibroGen Announces Completion of Patient Enrollment in ZEPHYRUS-2, a Phase 3 Clinical Study of Pamrevlumab in Idiopathic Pulmonary Fibrosis

03 4 2023 04:00:00 提供 Nasdaq GlobeNewswire

FibroGen Reports Fourth Quarter and Full Year 2022 Financial Results

27 2 2023 13:01:00 提供 Nasdaq GlobeNewswire

FibroGen to Present at Cowen’s 43rd Annual Health Care Conference

27 2 2023 04:00:00 提供 Nasdaq GlobeNewswire

FibroGen to Report Fourth Quarter and Full Year 2022 Financial Results

17 2 2023 04:00:00 提供 Nasdaq GlobeNewswire